Uncategorized

Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store

Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store

Published

14 hours ago

on

With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version